Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.

Biotechnology

Peptilogics

Jonathan Steckbeck

Marc Lesnick

Albert Fonticiella

Steve Kulp

Atul Deshpande Ph.d.

David Huang

Bradd Picone

Nicholas Pachuda

Nick Nystrom

The leadership team at Peptilogics has a wealth of experience in the biotech and pharmaceutical industries. Members of the team have worked as senior research engineers, directors of manufacturing, and adjunct assistant professors. They have also held positions as chief medical officers and lead computational biologists. In addition to their work experience, the team members have also received education from some of the top institutions in the country, including Saint Vincent College, the University of Pittsburgh, and the University of Illinois at Urbana-Champaign.

Leadership Team

CEO and Executive Team

Board of Directors

Leadership Team

About

Team members

Other teams at Peptilogics

CEO and Executive Team

Board of Directors